Valley Childrens Hospital
- Type
- Teaching hospital
- Where
- Madera, CA
- Medicare CCN
- 053300
- Received
- $194,706 in 89 records, 2021 ($1,688 general, $193,017 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: VALLEY CHILDRENS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 49 | $1,688 |
| 2021 | Research payment | 40 | $193,017 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $86,554 | 2021 |
| Gilead Sciences, Inc. | 6 | $59,225 | 2021 |
| PFIZER INC. | 3 | $19,584 | 2021 |
| Abbott Laboratories | 5 | $8,290 | 2021 |
| Novo Nordisk AS | 4 | $7,145 | 2021 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $6,143 | 2021 |
| GENZYME CORPORATION | 2 | $3,700 | 2021 |
| Incyte Corporation | 17 | $2,375 | 2021 |
| Johnson & Johnson Health Care Systems Inc. | 48 | $1,672 | 2021 |
| Stryker Corporation | 1 | $16 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 40 | $193,017 |
| Debt forgiveness | 48 | $1,672 |
| Long term medical supply or device loan | 1 | $16 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Stryker Corporation | $16 | Long term medical supply or device loan | In-kind items and services | SYSTEM 7 STRYKER PRECISION Device, SURGICAL | 2021 | |
| 2021-10-13 | Gilead Sciences, Inc. | $5,200 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2021 |
| 2021-09-01 | Gilead Sciences, Inc. | $3,550 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2021 |
| 2021-09-01 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $1,713 | Research payment | Cash or cash equivalent | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2021 | |
| 2021-08-26 | Johnson & Johnson Health Care Systems Inc. | $5 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-26 | Johnson & Johnson Health Care Systems Inc. | $4 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-08-09 | Incyte Corporation | $49 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-08-09 | Incyte Corporation | $42 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-08-09 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-08-09 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-08-09 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-08-09 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-08-05 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | 15mm Surgical Mechanical Aortic Valve PAS | 2021 |
| 2021-08-05 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | 15mm Surgical Mechanical Aortic Valve PAS | 2021 |
| 2021-08-02 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-07-28 | Abbott Laboratories | $1,216 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | 15mm Surgical Mechanical Aortic Valve PAS | 2021 |
| 2021-07-28 | Abbott Laboratories | $40 | Research payment | Cash or cash equivalent | MitraClip System Device, Structural Heart | 15mm Surgical Mechanical Aortic Valve PAS | 2021 |
| 2021-06-22 | Johnson & Johnson Health Care Systems Inc. | $156 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-22 | Johnson & Johnson Health Care Systems Inc. | $2 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-21 | Johnson & Johnson Health Care Systems Inc. | $76 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-06-11 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-06-11 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-06-08 | Incyte Corporation | $49 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-06-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-06-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-06-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-06-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-05-20 | Johnson & Johnson Health Care Systems Inc. | $17 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-20 | Johnson & Johnson Health Care Systems Inc. | $15 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-13 | Johnson & Johnson Health Care Systems Inc. | $31 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-13 | Johnson & Johnson Health Care Systems Inc. | $8 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-12 | Gilead Sciences, Inc. | $18,775 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2021 |
| 2021-05-04 | GENZYME CORPORATION | $2,200 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2021 |
| 2021-05-04 | Johnson & Johnson Health Care Systems Inc. | $51 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-05-04 | Johnson & Johnson Health Care Systems Inc. | $14 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-28 | Gilead Sciences, Inc. | $2,825 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2021 |
| 2021-04-28 | Johnson & Johnson Health Care Systems Inc. | $34 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-28 | Johnson & Johnson Health Care Systems Inc. | $6 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-23 | Novo Nordisk AS | $3,500 | Research payment | Cash or cash equivalent | NN8640-4263 | 2021 | |
| 2021-04-23 | Novo Nordisk AS | $2,000 | Research payment | Cash or cash equivalent | NN8640-4263 | 2021 | |
| 2021-04-23 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | NN8640-4263 | 2021 | |
| 2021-04-23 | Novo Nordisk AS | $645 | Research payment | Cash or cash equivalent | NN8640-4263 | 2021 | |
| 2021-04-21 | Johnson & Johnson Health Care Systems Inc. | $24 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-21 | Johnson & Johnson Health Care Systems Inc. | $5 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-19 | Johnson & Johnson Health Care Systems Inc. | $3 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-19 | Johnson & Johnson Health Care Systems Inc. | $1 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-14 | Abbott Laboratories | $4,033 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent Device, Vascular | 15mm Surgical Mechanical Aortic Valve PAS | 2021 |
| 2021-04-07 | PFIZER INC. | $3,314 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2021 | |
| 2021-04-06 | Johnson & Johnson Health Care Systems Inc. | $3 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-04-06 | Johnson & Johnson Health Care Systems Inc. | $3 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-31 | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | $4,430 | Research payment | Cash or cash equivalent | A Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy | 2021 | |
| 2021-03-30 | Johnson & Johnson Health Care Systems Inc. | $26 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-30 | Johnson & Johnson Health Care Systems Inc. | $25 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-24 | PFIZER INC. | $16,100 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2021 | |
| 2021-03-24 | PFIZER INC. | $170 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2021 | |
| 2021-03-24 | Johnson & Johnson Health Care Systems Inc. | $16 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-24 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-17 | Gilead Sciences, Inc. | $2,103 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2021 |
| 2021-03-17 | Johnson & Johnson Health Care Systems Inc. | $895 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-17 | Johnson & Johnson Health Care Systems Inc. | $5 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-17 | Johnson & Johnson Health Care Systems Inc. | $1 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-11 | Johnson & Johnson Health Care Systems Inc. | $5 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-11 | Johnson & Johnson Health Care Systems Inc. | $3 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-03 | Johnson & Johnson Health Care Systems Inc. | $4 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-03 | Johnson & Johnson Health Care Systems Inc. | $1 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-03-01 | Johnson & Johnson Health Care Systems Inc. | $38 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-23 | Johnson & Johnson Health Care Systems Inc. | $13 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-23 | Johnson & Johnson Health Care Systems Inc. | $4 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-17 | Gilead Sciences, Inc. | $26,772 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2021 |
| 2021-02-16 | Johnson & Johnson Health Care Systems Inc. | $20 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-16 | Johnson & Johnson Health Care Systems Inc. | $4 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-11 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-02-05 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-28 | Johnson & Johnson Health Care Systems Inc. | $22 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-28 | Johnson & Johnson Health Care Systems Inc. | $6 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-25 | GENZYME CORPORATION | $1,500 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2021 |
| 2021-01-21 | Johnson & Johnson Health Care Systems Inc. | $2 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-21 | Johnson & Johnson Health Care Systems Inc. | $1 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-13 | Johnson & Johnson Health Care Systems Inc. | $11 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-13 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-11 | Incyte Corporation | $49 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-01-11 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-01-11 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-01-11 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2021 | |
| 2021-01-08 | Johnson & Johnson Health Care Systems Inc. | $40 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-08 | Johnson & Johnson Health Care Systems Inc. | $11 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-04 | Johnson & Johnson Health Care Systems Inc. | $26 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-04 | Johnson & Johnson Health Care Systems Inc. | $16 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | $86,554 | Research payment | Cash or cash equivalent | A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Madera, CA, county Madera County, CA, state California; placed by its city name.
| Measure | Place (city or town) Madera, CA | County Madera County, CA | State California |
|---|---|---|---|
| Population B01003 | 67,831 | 160,940 | 39,287,377 |
| Population, 2020 census P1 | 66,224 | 156,255 | 39,538,223 |
| Median age B01002 | 30.4 | 34.6 | 37.9 |
| Under 18 B01001 | 30.8% | 27.1% | 22.0% |
| 65 and over B01001 | 9.6% | 14.4% | 15.7% |
| Households B11001 | 17,526 | 45,379 | 13,548,091 |
| Foreign born B05002 | 25.6% | 20.1% | 27.0% |
| Median household income B19013 | $63,933 | $76,627 | $99,122 |
| Median family income B19113 | $67,479 | $83,389 | $113,346 |
| Per capita income B19301 | $24,200 | $30,077 | $49,513 |
| Poverty rate B17001 | 25.6% | 19.2% | 12.0% |
| Unemployment rate B23025 | 12.6% | 10.1% | 6.6% |
| Civilian labor force B23025 | 29,997 | 69,012 | 20,068,466 |
| Mean commute (minutes) B08013 | 25.7 | 27.9 | 28.7 |
| Bachelor's degree or higher B15003 | 10.9% | 17.9% | 37.1% |
| Housing units B25001 | 18,562 | 51,015 | 14,644,735 |
| Owner-occupied B25003 | 54.7% | 67.5% | 55.9% |
| Renters B25003 | 45.3% | 32.5% | 44.1% |
| Median home value B25077 | $359,900 | $393,200 | $734,700 |
| Median gross rent B25064 | $1,353 | $1,390 | $2,036 |
| White, not Hispanic B03002 | 12.2% | 29.9% | 33.8% |
| Black B03002 | 2.9% | 2.4% | 5.2% |
| Hispanic or Latino B03002 | 81.1% | 60.9% | 40.2% |
| Asian B03002 | 1.3% | 2.4% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.4% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.
Comments